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Type 2 reactions (erythema nodosum leprosum [ENLI) are episodic, reactional states causing significant
morbidity in lepromatous leprosy patients. With a view to defining the immunological differences between the
stable and reactional forms of lepromatous leprosy, we determined antibody responses to LSR, a recombinant
protein ofMycobacterium Ieprae previously described by us (S. Laal, Y. D. Sharma, H. K. Prasad, A. Murtaza,
S. Singh, S. Tangri, R. S. Mishra, and I. Nath, Proc. Nati. Acad. Sci. USA 88:1054-1058, 1991), as well as to
10- to 15-mer overlapping peptides synthesized on the basis of the LSR amino acid sequence. We report here
the selective recognition of B cell epitopes by sera from patients with ENL as compared with a control group
with nonreactional lepromatous leprosy. Peptides 2 and 3, with the sequences GVTYEIDLTNKNAA and
IDLTNKNAAKLRGD, respectively, were recognized by >95% of sera from patients with active ENL. Peptide
3 in addition showed reactivity with sera taken from 91.6% of lepromatous leprosy patients who were
apparently stable but who were recorded to have had ENL several weeks before or after the sample collection.
The core sequence IDLTNKNAA common to both these peptides may be a major target of humoral responses
in ENL. In addition, the RGD motif at the C terminus appeared to influence the antigenicity of peptide 3 in
enzyme-linked immunosorbent assay. It would appear that humoral responses during ENL are directed to
selective antigenic determinants of the leprosy bacillus. The use of such serological markers to identify
lepromatous leprosy patients with a high risk for developing ENL would be of clinical and predictive value.
Leprosy has been intensively investigated in recent years
with a view to understanding the immunological basis for the
diverse clinical manifestations seen in subjects infected with
the same pathogen, viz., Mycobacterium leprae. The stable
forms of both the localized tuberculoid leprosy and the
disseminated lepromatous leprosy are characterized by hy-
popigmentation of the skin and local nerve thickening and
are relatively free of systemic symptoms (8, 15). However,
serious morbidity develops in some patients because of the
onset of episodic leprosy reactions. Of clinical significance is
the erythema nodosum leprosum reaction (ENL) (type 2
reaction), seen in 10 to 15% of lepromatous leprosy patients,
which leads to systemic manifestations of fever, generalized
erythematous dermal nodules, and arthritis (19). ENL often
occurs after institution of chemotherapy and acts as a
deterrent to specific drug therapy in those with repeated
episodes. During active ENL, patients have been reported to
have immunological features indicative of polyclonal B cell
activation, immune complex deposition (19), and develop-
ment of antigen-specific T cell functions in previously aner-
gic individuals (10, 12). Information on the antigenic deter-
minants that are the targets for these immune reactions is
lacking, and no clinical or laboratory markers are currently
available to identify individuals who are prone to ENL.
With the advent of DNA technology, an increasing num-
ber of M. leprae genes have been cloned and sequenced (4,
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21, 22). Recombinant antigens are now available for defining
the epitopes involved in immunological perturbation. Our
group has previously described a 135-kDa fusion protein
designated LSR (11) which had been identified from the
lambda gtll expression library of M. leprae (22) by using
lepromatous sera. This fusion protein, consisting of 89 amino
acids (aa) encoded by M. leprae DNA, was highly immuno-
reactive, being recognized by both T cells and sera of
leprosy patients. Sela et al. subsequently identified the full
gene from a cosmid library and showed that the total protein
had 123 aa with the LSR at the carboxy terminus (17). We
sought to identify differences in antibody recognition be-
tween stable and reactional leprosy patients by defining the
B cell epitopes of LSR. Overlapping peptides synthesized on
the basis of the amino acid sequence of LSR were used in
enzyme-linked immunosorbent assay (ELISA) with coded
serum samples from leprosy and tuberculosis patients as
well as healthy subjects from areas of India where leprosy is
endemic and from areas where it is not endemic.
MATERIALS AND METHODS
Subjects and sera. Coded sera from 294 leprosy patients
classified on the basis of the clinical and pathological criteria
of Ridley and Jopling (15) and from 18 healthy family
contacts (FC) were collected from areas of South India
where leprosy is endemic (VHS Leprosy Project, Shakthi
Nagar) as well as from the low-endemicity area of New
Delhi. In addition, sera from 40 healthy volunteers from the
region where leprosy is not endemic (NC) and from 46
pulmonary tuberculosis patients were included as controls.
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TABLE 1. Synthetic peptides of LSR used in ELISAM
Peptide no. Sequence Amino acid no.
1 EFGLDGVTYEIDLTNKNA 1-18
2 GVTYEIDLTNKNAA 6-19
3 IDLTNKNAAKLRGD 11-24
4 KNAAKLRGDLRQWVSAG 16-32
5 LRGDLRQWVSAGRRVG 21-36
6 RQWVSAGRRVGGRRRG 26-41
7 AGRRVGGRRRGRSNSG 31-46
8 GGRRRGRSNSGRGRG 36-50
9 GRSNSGRGRGAIDRREQSA 41-58
10 GRGRGAIDRREQSAA 46-59
11 AIDREQSAAIREWA 51-64
12 QSAAIREWARRNGHNV 56-71
13 REWARRNGHNVSTRGRI 61-77
14 RNGHNVSTRGRIPAD 66-80
15 VSTRGRIPADAVIDA 71-84
16 RIPADVIDAFHAAT 76-89
3-1 IDLTNKNAAKL 11-21
5-1 KLRGDLRQWVSAGRRVGG 20-37
a LSR sequence: E-lFGLDGVTYEIDLTNKNAAKLRGDLRQWVSAGR
RVGGRRRGRSNSGRGRGAIDREQSAAIREWARRNGHNVSTRGRI
PADVIDAFHAAT-89. Regions of pepties with significant 3-turn potential
(P > 1.5 X 10-4) are underlined.
Sera from areas where leprosy is endemic were sent by air
on ice packs to arrive in the laboratory within 24 h of the
sample collection. All sera were stored at -20°C prior to
testing and were decoded by the clinicians after the ELISA
results became available.
ELISA. ELISA was performed in 96-well plates (Maxi-
sorb-Immunoplates; Nunc Intermed, Kamstrup, Denmark)
coated overnight at 4°C with 50 RI1 of antigen (4 jig/ml) per
well in 50 mM bicarbonate buffer, pH 9.6. Antigen-coated
wells were washed three times with Tris-buffered saline (50
mM Tris and 150 mM NaCl, pH 7.4), and the uncovered
reactive sites were blocked with 1% fat-free, spray-dried
milk for 2 h at room temperature. Duplicate samples of sera
at 1:125, 1;250, and 1:500 dilutions were added (50 RI per
well), and the plates were incubated for 1 h at 37°C. The
plates were washed five times with Tris-buffered saline and
further incubated for 1 h at 37°C with 50 ,ul of a 1:1,000
dilution of peroxidase-conjugated rabbit anti-human total
immunoglobulin (Dakopatts A/S, Glostrup, Denmark). The
plates were washed as before, and a color reaction was
developed with 50 pu1 of 50 mg% o-phenylenediamine in 50
mM citrate-phosphate buffer, pH 5.0. After an incubation of
20 min at 37°C, the assay was terminated with 8 N H2SO4.
The optical density (OD) was determined at 492 nm. ELISA
data reported here refer to results obtained with sera diluted
to 1:125.
Antigens. Lysates of Escherichia coli expressing the LSR
antigen, control lysates containing the vector without the
insert, and sonicated armadillo-derived M. leprae were
prepared as described earlier. Eighteen peptides were syn-
thesized on the basis of the sequence of the LSR antigen
(Table 1). Sixteen were overlapping peptides of 15 to 19
amino acids, while peptides 3-1 and 5-1 represent defined
modifications of peptides 3 and 5, respectively. The peptides
were synthesized by the solid-phase method using t-Boc
chemistry (6) in polypropylene bags (74-p.m pore size) with
150 mg of p-methylbenzhydrylamine-HCl resin (Bachem
Inc., Torrance, Calif.). The resin was deprotonated by the
addition of 5% diisopropylethylamine (Merck, Darmstadt,
Germany) in dichloromethane (DCM) before introduction of
the first amino acid. The coupling cycle was initiated by
submerging the bags in a solution containing equimolecular
amounts of t-Boc amino acids (Bachem Inc.) and diisopro-
pylcarbodiimide (Merck) in 10 M excess over the available
amine in the bag. The reaction was allowed to proceed for 60
min, and the product was washed with DCM. The t-Boc
group of the newly coupled amino acids was removed with
55% trifluoroacetic acid (TFA) (Pierce, Rockford, Ill.) in
DCM. The reaction products were washed, and amino
groups were deprotonated with diisopropylethylamine. The
peptides were cleaved by treatment with 2 ml of 10% anisole
in anhydrous HF (Air Products and Chemicals Inc., Allen-
town, Pa.) for 60 min at 0°C. The peptides were subsequently
extracted with 5% acetic acid (Merck), analyzed, and puri-
fied by high-pressure liquid chromatography.
RESULTS
Antibody responses to LSR recombinant antigen. In con-
formity with our earlier data (11), LSR lysates reacted with
sera from >50% of all leprosy patients and FC but not with
any of the NC (Table 2). A given serum was designated
positive when the OD in ELISA exceeded 3 standard devi-
ations (SD) of the mean value obtained with sera from NC.
Sixty-five percent of sera from tuberculosis patients also
reacted to LSR, indicating the presence of cross-reactive
epitopes in the total protein.
Of significance was the enhanced (95%) seroreactivity
observed in ENL patients. All except 2 of 64 individuals
showed positive reactivity, with an OD (mean + SD) of
0.537 + 0.265. Of the 173 polar lepromatous leprosy patients
who appeared stable at the time of the sampling, 48 had a
history or clinical record of ENL. Of these, 44 (91.6%)
reacted with the LSR antigen (mean OD + SD, 0.309 ±
0.207). Eleven patients in this group developed clinical ENL
3 to 6 weeks after being tested. The others had single or
multiple reactional episodes from 4 weeks to several months
before the sampling.
Antibody response to synthetic peptides. In order to study
the fine specificity of the antibody recognition in the above-
described patients, 10- to 15-mer synthetic peptides spanning
the sequence of LSR (Table 1) were used as antigens in
ELISA. As expected, a higher percentage of ENL patients
than of stable lepromatous leprosy subjects reacted with
most peptides (Table 2). Of particular interest were peptides
2, 3, and 13, which were recognized by 93 to 95% of ENL
sera. Peptide 2 (GVTYEIDLTNKNAA) was recognized
only by sera from patients in the active phase of ENL. In
contrast, peptide 3 (IDLTNKNAAKLRGD), which shared a
core sequence of IDLTNKNAA, showed a broader reactiv-
ity with sera from both patients with active ENL and those
with a record of previous reactions. In addition, a lower
proportion (22 to 28.5%) of stable lepromatous, tuberculoid
leprosy patients and FC also showed seropositivity with
peptide 3. Interestingly, tuberculosis patients and NC did
not show antibodies to this peptide. It was not possible to
establish whether this subset of lepromatous leprosy patients
were undergoing subclinical reactions at the time of the
sample collection.
Peptide 13, which had a sequence that did not overlap with
those of peptides 1 and 3, also reacted in ELISA with 93% of
sera from patients with active ENL. However, it was
inferior as a predictor of ENL, as antibodies to this peptide
were detectable in only 12.5% of asymptomatic patients with
a history of reactions. The mean OD values obtained in
ELISA supported these observations (data not shown).
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TABLE 2. Percentages of seropositive subjects showing antibodies to overlapping peptides of LSR'
% of subjects with antibodies
Antigen ~~~~~~~Lepromatous (173)Antigen ENL Lepromatous(173) Tuberculoid TB FC NC
(44) H/O Stable (77) (46) (18) (40)(48) (125)
Peptide no.
1 47.7 8.3 4.8 3.8 0 5.5 0
2 95.4 8.3 8.0 6.4 0 0 0
3 95.4 91.6 28.0 28.5 0 22.2 0
4 59.0 47.9 32.8 42.8 0 16.6 0
5 81.8 12.5 48.8 55.8 63.0 44.4 10.0
6 86.3 20.8 40.8 57.1 89.0 27.7 10.0
7 77.2 87.5 74.4 79.2 0 61.1 2.5
8 36.3 64.5 20.8 14.2 0 5.5 0
9 56.8 43.7 25.6 18.1 17.3 16.6 2.0
10 47.7 25.0 12.8 7.7 0 5.5 2.5
11 79.5 22.9 28.8 41.5 69.5 22.2 0
12 88.6 18.7 29.6 22.0 69.5 11.1 0
13 93.1 12.5 22.4 12.9 17.3 22.2 2.5
14 40.9 16.6 10.4 22.0 0 5.5 0
15 27.2 18.7 31.2 16.8 80.4 22.2 0
16 45.4 14.5 38.5 40.2 0 22.2 0
LSR 95.4 91.6 61.6 51.0 63.0 56.0 0
MLS 97.7 93.7 96.8 71.0 69.5 83.0 13.0
a The mean OD ± SD obtained by ELISA with 1:125 dilutions of sera from NC was 0.047 + 0.016. Sera showing ODs of >0.1 (3 SD above the mean) were
considered seropositive. H/O, history of reactions; TB, pulmonary tuberculosis; lepromatous and tuberculoid, include both polar and borderline leprosy types
(15); MLS, sonicated M. leprae. Numbers in parentheses indicate the number of individuals tested.
Of the other peptides, peptide 7 bound to 74 to 87% of sera
from leprosy patients or their FC. It showed no cross-
reactivity with sera from tuberculosis patients and reacted
with only 1 of 40 sera from healthy NC. Peptides 5, 6, 11, and
12 reacted with sera from pulmonary tuberculosis patients,
indicating the presence of cross-reactive epitopes.
Antibody recognition of RGD motif in LSR. The relevance
of antibody binding by leprosy sera to the RGD motif of LSR
was explored by using synthetic peptides (Table 3). Peptide
3, which contained this motif, showed maximal binding
particularly in reactional patients. Peptide 3-1, in which
RGD was deleted, showed a significant reduction in binding
(P < 0.001). Of further interest was the decrease in antibody
binding when the position of this motif was altered. Thus,
peptide 4, which had RGD near the middle of the sequence,
showed a marked reduction, whereas peptide 5, with RGD
near the amino terminus, showed a lesser reduction in
binding to antibodies from the same leprosy patients. The
modified peptide 5-1, which had an additional lysine and
glycine at either end, showed a further loss in reactivity with
the same sera. The percentage of seropositive individuals
reacting to these peptides reflected the general pattern
observed with OD values.
These data taken together indicate that the major B cell
epitopes recognized by sera from ENL patients lie between
amino acids 11 and 24 of the LSR sequence and include
IDLTNKNAA and the RGD motif.
Relationship of local hydrophilicity regions in LSR to anti-
body recognition. On the basis of algorithms (3, 5), five
regions of local hydrophilicity were identifiable in the LSR
protein (Fig. 1). Of these, the first region from the N
terminus, i.e., aa 15 to 18, contains the core sequence
common to peptides 2 and 3. The second region contains
RGD. These areas correspond to the sequence mapped by
ENL sera in ELISA. The fifth region (aa 63 to 73) is
represented by peptide 13, which had also shown high
seroreactivity in ENL patients. The third region, spanning
aa 35 to 46 (peptides 6 and 7), appears to represent epitopes
commonly recognized by sera from patients with all leprosy
types but not by sera from tuberculosis patients. The fourth
region, represented by peptide 11, was not discriminatory
TABLE 3. Seroreactivity of stable and reactional lepromatous leprosy patients to peptides with and without the RGD motif'
Mean OD + SD (% seropositive subjects)
Peptide no. Lepromatous (n = 173)
ENL (n = 44)
H/O (n = 48) Stable (n = 125)
3 0.501 ± 0.338 (95.4) 0.181 + 0.139 (91.6) 0.103 + 0.236 (28)
3-1 0.023
_
0.059 (13.6) 0.010 + 0.032 (10.4) 0.001 ± 0.012 (1.6)
4 0.148 ± 0.166 (59) 0.091 ± 0.141 (47.9) 0.079 ± 0.159 (32.8)
5 0.325 ± 0.325 (81.8) 0.024 + 0.074 (12.5) 0.143 ± 0.204 (48.8)
5-1 0.084 ± 0.034 (27.2) 0.013 ± 0.043 (14.5) 0.0562 ± 0.087 (21.6)
a Sera were diluted to 1:125. Peroxidase-conjugated rabbit anti-human total immunoglobulin was diluted to 1:1,000. H/O, history of reaction. P < 0.001 for
peptide 3 versus peptide 3-1 for all three patient groups. (Freidman's test); P < 0.001 for peptide 3 versus peptide 18 for ENL and H/O patients.
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FIG. 1. Hydrophilicity graph of the 89-aa recombinant LSR
antigen of M. leprae, showing five regions of local hydrophilicity
(solid bars).
and showed variable antigenicity. Thus, the experimental
data correlated with the hydrophilicity regions of LSR.
DISCUSSION
Sera from lepromatous leprosy patients during the active
phase of type 2 reactions (ENL) show enhanced reactivity to
the recombinant LSR antigen compared with sera from
patients in the stable state. That this antigen may be differ-
entially recognized by individuals prone to type 2 reactions
is indicated by the increased seroreactivity of patients who
were clinically stable at the time of the sample collection but
had a record of previous or subsequent ENL. As no defini-
tive tests are currently available, it was not possible to rule
out subclinical episodes of ENL in these patients. That a
proportion of lepromatous leprosy patients were reacting to
cross-reactive epitopes in LSR was indicated by the fact that
63% of sera from tuberculosis patients also showed reactiv-
ity to the total antigen.
With a view to defining the fine specificity of the B cell
epitopes recognized by sera from ENL patients, overlapping
peptides spanning the LSR sequence were used as antigens.
As expected, there was a general enhancement in the hu-
moral responses of ENL patients to many of the peptides.
Of interest was the recognition of overlapping peptides 2
(GVTYEIDLTNKNAA) and 3 (IDLTNKNAAKLRGD) by
>95% of patients with active ENL. Whereas peptide 3 was
recognized by sera from both ENL patients and clinically
silent patients with a history of reactions, peptide 2, which
shared a core sequence of IDLTNKNAA, selectively re-
acted with the sera from patients in the active phase of ENL.
It would appear, therefore, that humoral responses during
active ENL are directed at selective epitopes as compared
with responses during the stable lepromatous state. The
sequence spanned by these peptides correlated with local
hydrophilicity regions in the algorithms generated for LSR.
In addition, these peptides had 1-turn potentials ofP > 1.5
X 10-4 (Table 1).
Furthermore, peptide 3 had an RGD motif at the C
terminus. This sequence is considered to be the basic unit of
the cell recognition system for adhesion to extracellular
matrices such as fibronectin and laminin. Monocytic cells
have fibronectin receptors that recognize the RGD sequence
(16). The presence of this motif in LSR may indicate cell
attachment sites in M. leprae which facilitate its entry into
macrophages, wherein it resides and multiplies. ENL pa-
tients have antibodies which appear to recognize the RGD
motif. Deletion of RGD significantly (P < 0.001) reduced the
antigenicity of peptide 3. Positional alterations of this motif
within the peptide also influenced seroreactivity. The ability
of antibodies to bind to the peptides was lowered when RGD
was present near the amino terminus or in the middle of the
overlapping peptides. Additional residues such as lysine and
glycine also hindered antibody binding. This conforms with
reports in which neighboring amino acids have been shown
to influence the conformation of peptides and subsequent
binding by antibodies (7, 13, 20). Taken together, the data
indicate that both the core sequence of 9 aa and the RGD
motif may be the major targets for immune recognition by B
cells in reactional leprosy patients.
It has been suggested that the majority of antibody-binding
epitopes on native proteins have discontinuous sequences
(1, 2). Recent studies on B cell epitope analysis of mycobac-
terial proteins have also indicated that sera from infected
patients primarily bound to nonlinear epitopes, whereas
murine monoclonal antibodies and hyperimmune sera bound
to linear epitopes (9, 14, 18). It is interesting that polyclonal
sera from ENL patients showed strong reactivity to contin-
uous or linear sequences from 6 to 24 aa of the LSR. The
emergence of antibodies to these epitopes during reactional
states may reflect a "hyperimmune" state. That this hyper-
immune state may also affect T cells is indicated by our
previous studies, in which we observed the emergence of
short-lived antigen-specific T cell responses in ENL patients
(10). Such perturbations of the immune response during
infection may be crucial for the development of ENL.
Whether this is due to immunoregulatory disturbances or
due to random uncovering of hitherto hidden or cryptic
epitopes requires further investigation. Alternatively, it is
possible that ENL patients have an inherent predisposition
to developing B cell responses to "harmful" epitopes.
Supporting this are follow-up studies which showed that 11
of the lepromatous leprosy patients with antibodies to pep-
tide 3 and with no clinical evidence of reaction at the time of
testing developed ENL 3 to 6 weeks later.
The humoral immune response to a living organism is the
result of a complex array of cellular and molecular interac-
tions. Mapping studies such as these may help in elucidating
the antigenic determinants of importance in discriminating
immune system events from pathologic events during natural
infections with whole organisms. In conclusion, peptides 2
and 3 may be candidate markers for identifying a subgroup of
lepromatous leprosy patients likely to develop debilitating
ENL. Identification of such patients prior to institution of
antileprosy treatment would help in better management of
lepromatous leprosy.
ACKNOWLEDGMENTS
This research was supported by the British Leprosy Relief Asso-
ciation (LEPRA) and the Commission of the European Communi-
ties, contract C11*-CT91-0087. Satish Singh is a recipient of a Senior
Research Fellowship of the Council for Scientific and Industrial
Research, Government of India.
We gratefully acknowledge the assistance of J. Tewani and P.
Tewani in manuscript preparation and U. Sengupta and S. K. Sinha
for helpful discussions.
VOL. 62, 1994
90 SINGH ET AL.
REFERENCES
1. Barlow, D. J., M. S. Edwards, and J. M. Thornton. 1986.
Continuous and discontinuous protein antigenic determinants.
Nature (London) 322:747-748.
2. Berzofsky, J. A. 1985. Intrinsic and extrinsic factors in protein
antigenic structure. Science 229:932-940.
3. Chou, P. Y., and G. D. Fasman. 1978. Prediction of the
secondary structure of proteins from their amino acid sequence.
Adv. Enzymol. Relat. Areas Mol. Biol. 47:45-149.
4. Clark-Curtiss, J. E., W. R. Jacobs, M. A. Doherty, L. R. Ritchie,
and R. Curtiss. 1985. Molecular analysis of DNA and construc-
tion of genomic libraries of Mycobactenum leprae. J. Bacteriol.
161:1093-1102.
5. Hopp, T. P., and K. R. Woods. 1981. Prediction of protein
antigenic determinants from amino acid sequences. Proc. Natl.
Acad. Sci. USA 78:3824-3828.
6. Houghten, R. A. 1985. General method for the rapid solid phase
synthesis of a large number of peptides. Specificity of antigen
antibody interaction at the level of individual amino acids. Proc.
Natl. Acad. Sci. USA 82:5131-5135.
7. Kabsch, W., and C. Sander. 1984. On the use of sequence
homologies to predict protein structure: identical pentapeptides
can have completely different conformations. Proc. Natl. Acad.
Sci. USA 81:1075-1078.
8. Kaplan, G., and Z. A. Cohn. 1986. The immunobiology of
leprosy. Int. Rev. Exp. Pathol. 28:45-78.
9. Klatser, P. R., M. Y. L. De Wit, A. H. J. Kolk, and R. A.
Hartskreel. 1991. Characterization of murine B-cell epitopes on
the Mycobacterium leprae proline-rich antigen by use of syn-
thetic peptides. Infect. Immun. 59:433-436.
10. Laal, S., L. K. Bhutani, and I. Nath. 1985. Natural emergence of
antigen-reactive T cells in lepromatous leprosy patients during
erythema nodosum leprosum. Infect. Immun. 50:887-892.
11. Laal, S., Y. D. Sharma, H. K. Prasad, A. Murtaza, S. Singh, S.
Tangri, R. S. Mishra, and I. Nath. 1991. Recombinant fusion
protein identified by lepromatous sera mimics native Mycobac-
tenum leprae in T cell responses across the leprosy spectrum.
Proc. Natl. Acad. Sci. USA 88:1054-1058.
12. Modlin, R. L., V. Mehra, R. Jordan, B. R. Bloom, and T. H.
Rea. 1986. In situ and in vitro characterization of the cellular
immune response in erythema nodosum leprosum. J. Immunol.
136:883-886.
13. Novotny, J., M. Handschumacher, and R. E. Bruccoleri. 1987.
Protein antigenicity: as static surface property. Immunol. Today
8:26-29.
14. Peake, P. W., W. J. Britton, M. P. Davenport, P. W. Roche, and
K. R. McKenzie. 1993. Analysis of B-cell epitopes in the
variable C-terminal region of the Mycobacterium leprae 70-
kilodalton heat shock protein. Infect. Immun. 61:135-141.
15. Ridley, D. S., and W. H. Jopling. 1966. Classification of leprosy
according to immunity. A five group system. Int. J. Leprosy
34:255-273.
16. Ruoslahti, E., and M. D. Pierschbacher. 1987. New perspectives
in cell adhesion: RGD and integrins. Science 238:491-497.
17. Sela, S., J. E. R. Thole, H. M. Ottenhoff, and J. E. Clark-
Curtiss. 1991. Identification of Mycobacterium leprae from a
cosmid library: characterization of a 15-kilodalton antigen that
is recognized by both humoral and cellular immune systems in
leprosy patients. Infect. Immun. 59:4117-4124.
18. Verbon, A., R. A. Hartskreel, and A. H. J. Kolk. 1991. Murine
and human B cell epitope mapping of the Mycobacterium
tuberculosis lOkDa heat shock protein using overlapping pep-
tides. Clin. Exp. Immunol. 86:6-12.
19. Wemambu, S. N. C., J. L. Turk, M. F. R. Waters, and R. J. W.
Rees. 1969. Erythema nodosum leprosum: a clinical manifesta-
tion of Arthus phenomenon. Lancet ii:933-935.
20. Wilson, I. A., D. H. Haft, E. D. Getzoff, J. A. Tainer, R. A.
Lerner, and S. Brenner. 1985. Identical short peptide sequences
in unrelated proteins can have different conformations: a testing
ground for theories of immune recognition. Proc. Natl. Acad.
Sci. USA 82:5255-5259.
21. Young, D. B., S. H. E. Kaufmann, P. W. M. Hermans, and
J. E. R. Thole. 1992. Mycobacterial protein antigens: a compi-
lation. Mol. Microbiol. 6:133-145.
22. Young, R. A., V. Mehra, D. Sweetser, T. M. Buchanan, J. E.
Clark-Curtiss, R. W. Davis, and B. R. Bloom. 1985. Gene for
major protein antigen of the leprosy parasite Mycobacterium
leprae. Nature (London) 316:450-452.
INFECT. IMMUN.
